Form 4: Zenas BioPharma Director Jason Nunn Receives 18,500 Stock Options

Zenas BioPharma, Inc. director Jason Raleigh Nunn was granted 18,500 stock options with an exercise price of $11.94, vesting fully on June 10, 2026.

Summary

• Jason Raleigh Nunn, a Director of Zenas BioPharma, Inc. (ZBIO), was granted 18,500 stock options.
• The transaction date for this grant was June 10, 2025.
• Each stock option has an exercise price of $11.94.
• The options will vest as to 100% of the underlying shares of common stock on June 10, 2026, which is the first anniversary of the vesting commencement date.
• Vesting is contingent upon Mr. Nunn's continued service to the company.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Mr. Nunn beneficially owns 18,500 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for aligning management incentives with shareholder value, reflecting standard corporate governance practices. It is a routine compensation disclosure rather than a major operational or financial announcement.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term value creation.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Risks

• The vesting of the stock options is subject to Jason Raleigh Nunn's continued service to Zenas BioPharma, Inc.

Future Outlook

The stock options granted to Director Jason Raleigh Nunn are set to vest fully on June 10, 2026, provided he continues his service to the company, and will expire on June 10, 2035, offering a long-term incentive.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align leadership interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options with a vesting schedule and an exercise price is a standard form of equity compensation for directors across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The 10-year expiration period for the options is typical for long-term incentive plans in the industry, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of stock options to Jason Raleigh Nunn, a director of Zenas BioPharma, Inc., constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, such compensation practices can set a precedent for performance-based incentives within the company.

Next Steps

• Jason Raleigh Nunn's continued service to Zenas BioPharma, Inc. for the options to vest on June 10, 2026.
• Potential exercise of the stock options by Jason Raleigh Nunn at or after the vesting date and before the expiration date.

Key Dates

Keywords

Zenas BioPharma, ZBIO, Form 4, stock option, insider transaction, director compensation, equity grant, beneficial ownership, corporate governance